Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease
Mitochondria has emerged as a critical ruler of metabolic reprogramming in immune responses and inflammation. In the context of colitogenic T cells and IBD, there has been increasing research interest in the metabolic pathways of glycolysis, pyruvate oxidation, and glutaminolysis. These pathways hav...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219422/full |
_version_ | 1797677005549862912 |
---|---|
author | Hoyul Lee Jae-Han Jeon Jae-Han Jeon Eun Soo Kim |
author_facet | Hoyul Lee Jae-Han Jeon Jae-Han Jeon Eun Soo Kim |
author_sort | Hoyul Lee |
collection | DOAJ |
description | Mitochondria has emerged as a critical ruler of metabolic reprogramming in immune responses and inflammation. In the context of colitogenic T cells and IBD, there has been increasing research interest in the metabolic pathways of glycolysis, pyruvate oxidation, and glutaminolysis. These pathways have been shown to play a crucial role in the metabolic reprogramming of colitogenic T cells, leading to increased inflammatory cytokine production and tissue damage. In addition to metabolic reprogramming, mitochondrial dysfunction has also been implicated in the pathogenesis of IBD. Studies have shown that colitogenic T cells exhibit impaired mitochondrial respiration, elevated levels of mROS, alterations in calcium homeostasis, impaired mitochondrial biogenesis, and aberrant mitochondria-associated membrane formation. Here, we discuss our current knowledge of the metabolic reprogramming and mitochondrial dysfunctions in colitogenic T cells, as well as the potential therapeutic applications for treating IBD with evidence from animal experiments. |
first_indexed | 2024-03-11T22:38:40Z |
format | Article |
id | doaj.art-497ad25f299f4dec871dd50f183a2318 |
institution | Directory Open Access Journal |
issn | 1664-3224 |
language | English |
last_indexed | 2024-03-11T22:38:40Z |
publishDate | 2023-09-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Immunology |
spelling | doaj.art-497ad25f299f4dec871dd50f183a23182023-09-22T09:28:17ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.12194221219422Mitochondrial dysfunctions in T cells: focus on inflammatory bowel diseaseHoyul Lee0Jae-Han Jeon1Jae-Han Jeon2Eun Soo Kim3Research Institute of Aging and Metabolism, Kyungpook National University, Daegu, Republic of KoreaResearch Institute of Aging and Metabolism, Kyungpook National University, Daegu, Republic of KoreaDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of KoreaDivision of Gastroenterology, Department of Internal Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of KoreaMitochondria has emerged as a critical ruler of metabolic reprogramming in immune responses and inflammation. In the context of colitogenic T cells and IBD, there has been increasing research interest in the metabolic pathways of glycolysis, pyruvate oxidation, and glutaminolysis. These pathways have been shown to play a crucial role in the metabolic reprogramming of colitogenic T cells, leading to increased inflammatory cytokine production and tissue damage. In addition to metabolic reprogramming, mitochondrial dysfunction has also been implicated in the pathogenesis of IBD. Studies have shown that colitogenic T cells exhibit impaired mitochondrial respiration, elevated levels of mROS, alterations in calcium homeostasis, impaired mitochondrial biogenesis, and aberrant mitochondria-associated membrane formation. Here, we discuss our current knowledge of the metabolic reprogramming and mitochondrial dysfunctions in colitogenic T cells, as well as the potential therapeutic applications for treating IBD with evidence from animal experiments.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219422/fullmitochondriaIBD - inflammatory bowel diseaseimmunometabolismT celltreatmentinflammation |
spellingShingle | Hoyul Lee Jae-Han Jeon Jae-Han Jeon Eun Soo Kim Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease Frontiers in Immunology mitochondria IBD - inflammatory bowel disease immunometabolism T cell treatment inflammation |
title | Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease |
title_full | Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease |
title_fullStr | Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease |
title_full_unstemmed | Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease |
title_short | Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease |
title_sort | mitochondrial dysfunctions in t cells focus on inflammatory bowel disease |
topic | mitochondria IBD - inflammatory bowel disease immunometabolism T cell treatment inflammation |
url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219422/full |
work_keys_str_mv | AT hoyullee mitochondrialdysfunctionsintcellsfocusoninflammatoryboweldisease AT jaehanjeon mitochondrialdysfunctionsintcellsfocusoninflammatoryboweldisease AT jaehanjeon mitochondrialdysfunctionsintcellsfocusoninflammatoryboweldisease AT eunsookim mitochondrialdysfunctionsintcellsfocusoninflammatoryboweldisease |